Screener
Vir Biotechnology, Inc. VIR Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -92.4%+3,099pp | -720.8%+2,379pp | -699.2%+92.1pp | -3,253.6%-2,479pp | -3,191.7%-2,476pp | |
| Net margin | -83%+2,813pp | -676%+2,093pp | -638.9%+64.5pp | -2,963.5%-2,285pp | -2,895.9%-2,284pp | |
| Returns | ||||||
| Return on equity | -26.1%+20.1pp | -47.7%-3.1pp | -45.7%-7.6pp | -49.1%-12.5pp | -46.2%-16.4pp | |
| Return on invested capital | -36.6%+24.8pp | -67.6%-10.3pp | -61.8%-12.5pp | -60.7%-10.4pp | -61.4%-16.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.2× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 6×-1.0× | 7.1×+0.3× | 5.5×-3.2× | 7.3×-1.7× | 7×-5.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.82-15.0% | $5.52-27.4% | $5.52-34.6% | $5.73-36.9% | $6.84-35.0% | |
| Valuation | ||||||
| Market capitalization | $1.48B+111% | $1.43B+61.1% | $838.92M-17.0% | $793.21M-22.3% | $728.51M-39.5% | |
| Price / sales | 4.9×-32.1× | 21.9×-20.7× | 12.2×-1.4× | 47×+34.1× | 38.3×+23.1× | |
| Price / book | 1.5×+0.8× | 1.8×+0.9× | 1.1×+0.2× | 1×+0.2× | 0.8×-0.1× |
FAQ
- What are Vir Biotechnology, Inc.'s profit margins?
- Vir Biotechnology, Inc. (VIR) runs a 96.1% gross margin and a -92.4% operating margin, with a -83.0% net margin.
- Where do Vir Biotechnology, Inc.'s ratios come from?
- Every ratio is computed from Vir Biotechnology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
